Literature DB >> 10911812

Understanding non-compliance with treatment in adults with cystic fibrosis.

M E Dodd1, A K Webb.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10911812      PMCID： PMC1305877     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  26 in total

1.  Compliance and self-medication in cystic fibrosis.

Authors:  A Meyers; T F Dolan; D Mueller
Journal:  Am J Dis Child       Date:  1975-09

2.  Typologies of nonadherence in cystic fibrosis.

Authors:  G P Koocher; M L McGrath; L J Gudas
Journal:  J Dev Behav Pediatr       Date:  1990-12       Impact factor: 2.225

Review 3.  Contemporary psychosocial issues in cystic fibrosis: treatment adherence and quality of life.

Authors:  J Abbott; L Gee
Journal:  Disabil Rehabil       Date:  1998 Jun-Jul       Impact factor: 3.033

4.  A comparative study of the psychosocial assets of adults with cystic fibrosis and their healthy peers.

Authors:  S L Shepherd; M F Hovell; I R Harwood; L E Granger; C R Hofstetter; C Molgaard; R M Kaplan
Journal:  Chest       Date:  1990-06       Impact factor: 9.410

5.  Self-administration of drugs for cystic fibrosis.

Authors:  M Trapp; S Barton; H Morgan; L Lockyer
Journal:  Prof Nurse       Date:  1998-12

6.  Psychosocial adaptation in older cystic fibrosis patients.

Authors:  G D Strauss; D K Wellisch
Journal:  J Chronic Dis       Date:  1981

7.  Low bone mineral density in adults with cystic fibrosis.

Authors:  C S Haworth; P L Selby; A K Webb; M E Dodd; H Musson; R McL Niven; G Economou; A W Horrocks; A J Freemont; E B Mawer; J E Adams
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

8.  Medical compliance and coping with cystic fibrosis.

Authors:  D R Czajkowski; G P Koocher
Journal:  J Child Psychol Psychiatry       Date:  1987-03       Impact factor: 8.982

9.  Patient-reported compliance with cystic fibrosis therapy.

Authors:  M A Passero; B Remor; J Salomon
Journal:  Clin Pediatr (Phila)       Date:  1981-04       Impact factor: 1.168

10.  Compliance among adults with cystic fibrosis.

Authors:  S L Fong; R E Dales; M G Tierney
Journal:  DICP       Date:  1990 Jul-Aug
View more
  12 in total

1.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

2.  Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.

Authors:  Ivanka Galeva; Michael W Konstan; Mark Higgins; Gerhild Angyalosi; Florian Brockhaus; Simon Piggott; Karen Thomas; Alexander G Chuchalin
Journal:  Curr Med Res Opin       Date:  2013-06-05       Impact factor: 2.580

Review 3.  Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  Daniel Conole; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

4.  Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis.

Authors:  J Thornton; R Elliott; M P Tully; M Dodd; A K Webb
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

5.  User Needs in the Development of a Health App Ecosystem for Self-Management of Cystic Fibrosis: User-Centered Development Approach.

Authors:  Jacqueline Floch; Annabel Zettl; Lena Fricke; Tina Weisser; Lisbet Grut; Thomas Vilarinho; Erlend Stav; Antonio Ascolese; Cornelia Schauber
Journal:  JMIR Mhealth Uhealth       Date:  2018-05-08       Impact factor: 4.773

6.  Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data.

Authors:  Héloïse Rouzé; Marie Viprey; Samuel Allemann; Alexandra L Dima; Pascal Caillet; Angélique Denis; Stéphanie Poupon-Bourdy; Boubou Camara; Catherine Llerena; Philippe Reix; Isabelle Durieu; Quitterie Reynaud; Sandrine Touzet
Journal:  Patient Prefer Adherence       Date:  2019-09-04       Impact factor: 2.711

7.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

8.  Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.

Authors:  Antje Schuster; Cynthia Haliburn; Gerd Döring; Martin Harris Goldman
Journal:  Thorax       Date:  2012-11-07       Impact factor: 9.139

9.  Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.

Authors:  L Ting; S Aksenov; S G Bhansali; R Ramakrishna; P Tang; D E Geller
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-12

10.  Users' Experiences of a Mobile Health Self-Management Approach for the Treatment of Cystic Fibrosis: Mixed Methods Study.

Authors:  Jacqueline Floch; Thomas Vilarinho; Annabel Zettl; Gema Ibanez-Sanchez; Joaquim Calvo-Lerma; Erlend Stav; Peter Halland Haro; Asbjørn Lein Aalberg; Alvaro Fides-Valero; José Luis Bayo Montón
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-08       Impact factor: 4.773
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.